AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal

Agios Pharmaceuticals (AGIO) reported a loss of $1.69 per share in second-quarter 2024, wider than the Zacks Consensus Estimate of a loss of$1.58. In the year-ago quarter, the company reported a loss of $1.51.AGIO reported revenues of$8.6 million, which missed the Zacks Consensus Estimate of $9.4 million. In the year-ago quarter, the company recorded revenues of$6.7 million.Quarter in DetailIn the reported quarter, revenues were generated entirely from product revenues of Agios’ only marketed drug, Pyruk ...